|
| |
|
| |
|
| |
Welcome to PharmaShots Weekly
| | | Feb 23 Edition
|
|
| | PharmaShots Weekly is your Monday signal check: a fast, story-driven run-through of the deals, data, approvals, and platforms that actually shift the biopharma landscape.
|
|
|
|
|
| |
Hims & Hers Goes Global: $1.15B Eucalyptus Acquisition Accelerates Growth
|
|
| | $1.8B AI Leap: Unnatural Products & Novartis Target Hard-to-Drug Heart Conditions
|
|
| | Dual Impact: Lilly Shows Taltz + Zepbound Reduces Psoriasis & Supports Weight Loss
|
|
| | Weight Management Upgrade: EC Approves Higher Wegovy Dose
|
|
|
|
|
| |
Stay Curious.
| | | Stay informed!
|
|
| | Stay ahead with PharmaShots Weekly!
|
|
|
|
|
| |
|
| |
|
| |
Cover Story
|
| |
Supreme Court Tariff Ruling: What It Means for Pharma and Biotech
|
| |
Major Deals & Strategic Partnerships
|
| |
| • | Unnatural Products & Novartis: $1.8B AI-Powered Cardiovascular Collaboration
|
|
| • | Candel Therapeutics: $100M Royalty Deal Ahead of Regulatory Milestone
|
|
| • | Hims & Hers: $1.15B Acquisition of Eucalyptus
|
|
| • | VB Spine & Augmedics: Exclusive xvision System Deal for AR-Guided Spine Surgery
|
|
| |
Clinical & Pipeline Updates
|
| |
Neurology & Migraine
|
| |
| • | Lundbeck: Phase IIb PROCEED topline results for bocunebart
|
|
| |
Nephrology
|
| |
| • | Genentech: Phase III MAJESTY results for Gazyva in Primary Membranous Nephropathy
|
|
| |
Immunology & Autoimmune Disorders
|
| |
| • | InnoCare Pharma: Phase II/III trials of soficitinib in CSU, atopic dermatitis, vitiligo, psoriasis
|
|
| • | Novartis: Phase III RemIND results for oral remibrutinib in CIndU
|
|
| • | Teva & Sanofi: RELIEVE UCCD LTE results for duvakitug in UC/CD
|
|
| |
Oncology & Rare Cancers
|
| |
| • | Lilly: Phase III LIBRETTO-432 topline for Retevmo in RET+ NSCLC
|
|
| • | Pfizer: Phase III BREAKWATER Cohort 3 topline for Braftovi + cetuximab in BRAF V600E mCRC
|
|
| |
Dermatology & Metabolic Health
|
| |
| • | Lilly: Phase IIIb TOGETHER-PsO results for Taltz + Zepbound in psoriasis + overweight patients
|
|
| |
Pediatrics
|
| |
| • | Takeda: Phase III KEPLER results for ENTYVIO in pediatric UC
|
|
| |
Regulatory & Approvals
|
| |
Biopharma
|
| |
| • | CStone Pharmaceuticals: FDA IND clearance for CS2009 in advanced solid tumors
|
|
| • | GSK: EC approval for Exdensur in asthma & CRSwNP
|
|
| • | Bristol Myers Squibb: FDA NDA acceptance for iberdomide combo in multiple myeloma
|
|
| • | Cytokinetics: EC approval for Myqorzo in oHCM
|
|
| • | Novo Nordisk: EC approval for higher Wegovy dose
|
|
| • | ImmunityBio: EC conditional approval for Anktiva + BCG in NMIBC
|
|
| • | Daiichi Sankyo: EMA validation of MAA for Enhertu
|
|
| • | Roche: FDA NDA acceptance for giredestrant
|
|
| • | NexEos Bio: FDA IND clearance for NTX-1024
|
|
| |
MedTech Regulatory Update
|
| |
| • | LEX Diagnostics: FDA 510(k) & CLIA Waiver for VELO System
|
|
| • | Bio-Techne: CE-IVD marking for Ella Platform
|
|
| |
Biosimilars Regulatory Update
|
| |
| • | STADA & Bio-Thera: EC approval for Gotenfia (Simponi biosimilar)
|
|
| • | Henlius: FDA IND clearance for HLX15-SC (Darzalex Faspro biosimilar)
|
|
| • | Accord BioPharma: FDA approval for Filkri (Neupogen biosimilar)
|
|
| |
Animal Health
|
| |
| • | Cencora & Covetrus: $3.5B Merger to Build Integrated Animal Health Platform
|
|
| • | Boehringer Ingelheim: FDA EUA for NexGard & NexGard COMBO against New World Screwworm
|
|
| |
|
| |
|
| |
|
| |
|
| |
Celebrating Innovation and Excellence Across the Global Pharma & Healthcare Industry
|
| |
We are thrilled to announce the PharmaShots Pharma Awards 2026, a premier virtual event dedicated to recognizing groundbreaking innovation, leadership, and excellence in the pharmaceutical and healthcare sectors worldwide.
|
| |
This prestigious initiative brings together industry leaders, innovators, and key decision-makers from around the globe, creating a unique platform to celebrate achievements and set new benchmarks for the industry.
|
| |
Why Partner with PharmaShots Pharma Awards?
|
| |
Our sponsorship opportunities allow partners to:
|
| |
| • | Showcase your brand in front of a highly engaged, global pharma audience.
|
|
| • | Position your organization as a leader in innovation and thought leadership.
|
|
| • | Gain exclusive networking access to decision-makers, innovators, and influencers shaping the future of healthcare.
|
|
| |
We are currently reaching out to potential sponsors to understand your engagement goals and preferred sponsorship avenues. Based on your input, our team will provide a customized sponsorship prospectus detailing benefits, opportunities, and recommended next steps.
|
| |
Date of Awards Announcement: May 1, 2026
|
| |
We invite organizations to join us in this landmark celebration. Your support will help us highlight excellence, inspire innovation, and strengthen connections across the global pharma ecosystem.
|
| |
Interested in exploring sponsorship opportunities?
Partner with us at the PharmaShots Pharma Awards, fill out your sponsorship form here
|
| |
|
| |
|
| |
Supreme Court Tariff Ruling: What It Means for Pharma and Biotech
|
| |
|
| |
On February 20, 2026, the U.S. Supreme Court struck down the sweeping tariffs imposed by President Donald Trump, ruling that the President exceeded his authority under the International Emergency Economic Powers Act (IEEPA). While the decision primarily addresses trade and constitutional limits, its ripple effects are profound for the pharmaceutical and biotech sectors.
|
| |
Regulatory & Trade Implications for Pharma
|
| |
Imported APIs and Raw Materials: U.S. pharma relies heavily on imported active pharmaceutical ingredients (APIs) and excipients. Tariffs on these critical inputs previously raised costs for drug manufacturers, slowed production, and disrupted supply chains. The ruling removes these extra costs, potentially easing pressure on drug pricing.
Medical Devices & Biotech Equipment: Many high-tech instruments and components come from Europe and Asia. Eliminating tariffs may reduce capital expenditure, enabling faster adoption of new technologies and R&D equipment.
Global Clinical Trials & Partnerships: The decision clarifies trade rules, giving multinational pharma firms greater certainty when sourcing materials, exporting investigational drugs, and negotiating cross-border contracts.
Economic Relief, But Caution Ahead
|
| |
The billions in tariff revenue collected over the past year are now in legal limbo, creating uncertainty for budget forecasting, including federal funding for healthcare programs.
While costs for imports may drop, sector-specific duties under national security statutes remain, so pharma companies must continue careful compliance planning.
Strategic Takeaways for Pharma Leaders
|
| |
Reassess Supply Chains: With tariffs lifted, firms can optimize sourcing strategies, reduce reliance on domestic substitutes, and lower overall production costs.
Reevaluate Drug Pricing: Lower import costs for APIs could help ease pricing pressures, especially for generic and biosimilar manufacturers.
Investment in Innovation: Savings from tariff relief can be reinvested into R&D, clinical trials, and digital health initiatives.
Policy Advocacy: The ruling underscores the importance of legal clarity for pharma, reminding industry stakeholders to engage proactively with trade and regulatory policy.
Global Pharma Outlook
|
| |
The Supreme Court decision signals a shift toward more predictable U.S. trade policy, which is critical for pharma companies operating across continents. As tariffs recede, the U.S. market becomes more attractive for international partnerships, while domestic producers may need to adjust to increased competition.
|
| |
Bottom Line: For pharma and biotech, the ruling is more than a legal or political story it’s a strategic inflection point. Lowered input costs, stabilized supply chains, and clearer trade rules create opportunities for growth, innovation, and global collaboration in 2026 and beyond.
|
| |
|
| |
| | $1.8B AI Macrocycle Deal: Unnatural Products & Novartis Target Heart Disease
|
|
|
|
|
| |
$1.8B AI Macrocycle Deal: Unnatural Products & Novartis Target Cardiovascular Breakthrough
|
| |
|
| |
Unnatural Products (UNP) has entered a high-value research collaboration and licensing agreement with Novartis to advance an undisclosed cardiovascular program powered by UNP’s AI-enhanced macrocycle platform.
|
| |
Why It Matters
|
| |
| • | Mega Deal: ~$100M upfront and pre-IND milestones; up to ~$1.7B in total milestones.
|
|
| • | Financial Upside: Tiered royalties from mid-single to low double digits on net sales.
|
|
| • | Tech Leap: AI-driven macrocycles target complex cardiovascular challenges.
|
|
| • | Strategic Bet: Validates platform biotech for hard-to-drug indications.
|
|
| |
Strategic Focus
|
| |
| • | AI Innovation: Enhances Novartis’ cardio pipeline with precision macrocycles.
|
|
| • | Platform Power: UNP’s tech unlocks previously intractable targets.
|
|
| • | Cardio Push: Addresses high-unmet needs in cardiovascular disease.
|
|
| • | Momentum Signal: Boosts AI-enabled small-molecule engineering frontier.
|
|
| |
This partnership highlights the growing role of AI-driven macrocycle engineering in tackling complex cardiovascular targets—and signals continued momentum for platform-based biotech innovation.
|
| |
|
| |
| | Hims & Hers Bets Big on Global Expansion with $1.15B Eucalyptus Deal
|
|
|
|
|
| |
Hims & Hers Expands Globally with $1.15B Eucalyptus Deal
|
| |
|
| |
Hims & Hers Health has entered a definitive agreement to acquire Eucalyptus in a transaction valued at up to ~$1.15B, marking a transformative step in its international growth strategy.
|
| |
Why It Matters
|
| |
| • | Mega Acquisition: Up to ~$1.15B deal accelerates non-U.S. scaling.
|
|
| • | Financial Structure: ~$240M cash upfront; rest tied to milestones.
|
|
| • | Market Entry: Boosts presence in Australia, Japan, UK, Germany, and Canada.
|
|
| • | Strategic Bet: Merges digital health platforms for global consumer reach.
|
|
| |
Strategic Focus
|
| |
| • | Global Expansion: Leverages Eucalyptus’ regional expertise and infrastructure.
|
|
| • | Platform Synergy: Builds unified, localized digital health offerings.
|
|
| • | Consumer Push: Targets international telehealth and personalized care.
|
|
| • | Growth Frontier: Positions Hims & Hers as a leading worldwide brand.
|
|
| |
With this move, Hims & Hers signals clear intent: scale beyond the U.S., deepen localized offerings, and solidify its standing as a leading international digital health brand.
|
| |
| | Financing and Innovation: Candel and VB Spine Make Bold Moves
|
|
|
|
|
| |
Candel Secures $100M Royalty Deal Ahead of Key Regulatory Milestone
|
| |
|
| |
Candel Therapeutics has entered a $100M royalty funding agreement with RTW Investments, contingent on FDA approval of aglatimagene besadenovec (CAN-2409) for intermediate- to high-risk localized prostate cancer.
|
| |
Under the terms, RTW will receive a capped, tiered single-digit percentage of U.S. annual net sales of aglatimagene aligning long-term value creation with commercial performance.
|
| |
Candel plans a Q4 2026 BLA submission, following successful Phase IIa in NSCLC/PDAC and a pivotal Phase III in prostate cancer under FDA SPA.
|
| |
Why It Matters
|
| |
| • | Strategic Financing: $100M royalty deal tied to FDA approval and U.S. sales.
|
|
| • | Clinical Momentum: Phase III complete in prostate cancer; Phase IIa successes in NSCLC/PDAC.
|
|
| • | Regulatory Path: BLA submission slated for Q4 2026 under FDA SPA.
|
|
| • | Value Alignment: Capped royalties link funding to commercial upside.
|
|
| |
Strategic Focus
|
| |
| • | Immunotherapy Push: Positions CAN-2409 as frontline solid tumor therapy.
|
|
| • | Platform Validation: Reinforces viral immunotherapy for hard-to-treat cancers.
|
|
| • | Commercial Prep: Secures runway ahead of potential approval.
|
|
| • | Investor Signal: Boosts confidence in late-stage execution.
|
|
| |
With late-stage data in hand and financing secured ahead of regulatory submission, Candel is positioning CAN-2409 at the forefront of immunotherapy-driven approaches in solid tumors—while reinforcing investor confidence in its commercialization pathway.
|
| |
VB Spine Secures Exclusive Rights to Augmedics’ xvision System, Advancing AR-Guided Spine Surgery
|
| |
VB Spine has entered a definitive agreement with Augmedics to secure exclusive rights to the xvision Spine System—bringing advanced AR navigation into its visualization portfolio.
|
| |
Why It Matters
|
| |
| • | Strategic Acquisition: Exclusive rights to AR-guided xvision platform.
|
|
| • | Tech Leap: Real-time anatomical overlays on the operative field.
|
|
| • | Surgeon Benefits: Boosts accuracy, efficiency; cuts radiation exposure.
|
|
| • | Portfolio Power: Expands VB Spine’s precision tools for complex cases.
|
|
| |
Strategic Focus
|
| |
| • | Visualization Expansion: Merges AR with open surgery familiarity.
|
|
| • | Procedural Push: Targets full spectrum of spine interventions.
|
|
| • | Precision Play: Redefines planning and execution in spine care.
|
|
| • | Innovation Frontier: Drives immersive tech for surgical workflows.
|
|
| |
With this move, VB Spine strengthens its commitment to precision-driven spine care, leveraging immersive AR technology to redefine how surgeons see, plan, and execute complex procedures.
|
| |
|
| |
| | Clinical Wins Across Migraine, Cancer, and Autoimmune Therapies
|
|
|
|
|
| |
Phase IIb PROCEED Study by Lundbeck
|
| |
|
| |
Migraine
|
| |
Lundbeck reports positive Phase IIb PROCEED topline results for bocunebart (SC/IV; once monthly for three months) vs. placebo in 431 patients across 14 countries with migraine who failed 1–4 prior preventive therapies.
|
| |
Key Details
|
| |
| • | Met primary endpoint in multiple IV dosing arm with statistically significant reduction in monthly migraine days over Weeks 1–12.
|
|
| • | Global, robust dataset in difficult-to-treat population; additional analyses ongoing for dose-response and optimization.
|
|
| |
Next Steps
Full results for upcoming scientific conference and peer-reviewed publication; regulator engagement planned for Phase III design.
|
| |
Asset Snapshot
Encouraging mid-stage data in refractory migraine, bolstering Lundbeck's neurology pipeline for unmet needs.
|
| |
With PROCEED's results, Lundbeck advances toward expanded options for hard-to-treat migraine patients.
|
| |
Primary Membranous Nephropathy (PMN)
|
| |
|
| |
Genentech reports positive Phase III MAJESTY topline results for Gazyva (obinutuzumab) vs. tacrolimus in 142 patients with PMN.
|
| |
Key Details
|
| |
| • | Met primary endpoint with higher complete remission (CR) rate at Week 104.
|
|
| • | Achieved key secondary endpoints: improved overall remission at Week 104 and higher CR at Week 76, showing durable response.
|
|
| |
Next Steps
Data presentation at upcoming scientific forum; regulatory discussions with FDA, EMA, and global authorities. Ongoing Phase II in pediatric lupus nephritis.
|
| |
Asset Snapshot
Strengthens Genentech's nephrology pipeline with targeted B-cell therapy for rare renal disorders.
|
| |
MAJESTY positions Gazyva as a potential advance in immune-mediated kidney diseases.
|
| |
Multiple Autoimmune Indications
|
| |
InnoCare Pharma doses first patient in Phase II/III trial of soficitinib (ICP-332, oral TYK2 inhibitor) for chronic spontaneous urticaria (CSU); completes enrollment in parallel trials for atopic dermatitis and vitiligo.
|
| |
Key Details
|
| |
| • | Phase III enrollment complete in moderate-to-severe atopic dermatitis.
|
|
| • | Phase II enrollment complete in vitiligo; advancing in psoriasis and nodular prurigo.
|
|
| • | Selective TYK2 inhibitor targeting T-cell-mediated autoimmune diseases.
|
|
| |
Next Steps
Multiple pivotal and mid-stage programs progressing, expanding immunology pipeline.
|
| |
Asset Snapshot
Differentiated oral option for high-burden inflammatory dermatology and autoimmune conditions.
|
| |
Soficitinib positions InnoCare for broad impact in TYK2-driven diseases.
|
| |
RET+ Non-Small Cell Lung Cancer (NSCLC)
|
| |
|
| |
Lilly reports positive Phase III LIBRETTO-432 topline results for Retevmo (selpercatinib) vs. placebo in 151 early-stage (II–IIIA) RET fusion-positive NSCLC patients post-surgery/radiotherapy (adjuvant setting).
|
| |
Key Details
|
| |
| • | Met primary endpoint with significant improvement in investigator-assessed event-free survival (EFS).
|
|
| • | Immature OS data show favorable trend; potent, selective RET inhibitor with CNS activity.
|
|
| |
Next Steps
Full results for upcoming scientific meeting, peer-reviewed publication, and global regulatory discussions.
|
| |
Asset Snapshot
Advances Retevmo into earlier lines, reinforcing Lilly's precision oncology in RET-driven cancers.
|
| |
LIBRETTO-432 supports potential expansion for improved long-term outcomes in RET+ NSCLC.
Irritable Bowel Diseases
|
| |
|
| |
Teva and Sanofi report positive long-term extension (LTE) data from RELIEVE UCCD Phase IIb trial for duvakitug (450/900 mg SC Q4W) in 130 UC/CD patients post-induction.
|
| |
Key Details
|
| |
| • | UC (Week 44): 58% (900 mg) and 47% (450 mg) clinical remission (mMS).
|
|
| • | CD (Week 44): 55% (900 mg) and 41% (450 mg) endoscopic response (SES-CD).
|
|
| • | Durable benefits across endpoints, building on Week 14 induction vs. placebo.
|
|
| |
Next Steps
Supports advancement in UC and CD, bolstering partners' immunology pipeline.
|
| |
Asset Snapshot
Differentiated IBD option with sustained remission and endoscopic improvements.
|
| |
RELIEVE UCCD positions duvakitug for high-burden gastrointestinal diseases.
BRAF V600E Mutated Metastatic Colorectal Cancer (mCRC)
|
| |
Pfizer reports positive Phase III BREAKWATER Cohort 3 topline results for Braftovi (encorafenib, 300 mg PO QD) + cetuximab + FOLFIRI (n=73) vs. FOLFIRI ± Avastin (n=74) in first-line BRAF V600E mCRC.
|
| |
Key Details
|
| |
| • | Improved progression-free survival (PFS) by BICR; meaningful overall survival (OS) prolongation.
|
|
| • | ORR data presented at ASCO GI 2026, showing clinical activity in high-risk population.
|
|
| |
Next Steps
Detailed findings for upcoming meeting; FDA submission for first-line approval.
|
| |
Asset Snapshot
Advances Pfizer's precision oncology in poor-prognosis BRAF-mutated mCRC.
|
| |
BREAKWATER Cohort 3 supports Braftovi combo as potential first-line standard.
|
| |
Chronic Inducible Urticaria (CIndU)
|
| |
Novartis reports positive Phase III RemIND topline results for oral remibrutinib vs. placebo in adults with H1-antihistamine-inadequate CIndU.
|
| |
Key Details
|
| |
| • | Met primary endpoint with significantly higher complete response rates at Week 12 across symptomatic dermographism, cold urticaria, and cholinergic urticaria.
|
|
| |
Next Steps
sNDA submitted to FDA for symptomatic dermographism; global filings and scientific presentation upcoming.
|
| |
Asset Snapshot
Oral option strengthening Novartis' immunology portfolio in mast cell-driven diseases.
|
| |
RemIND positions remibrutinib for difficult-to-control CIndU.
|
| |
Psoriasis & Weight Management
|
| |
|
| |
Lilly reports positive Phase IIIb TOGETHER-PsO topline results for Taltz (ixekizumab) + Zepbound (tirzepatide) vs. Taltz alone in 274 overweight/obese adults with moderate-to-severe plaque psoriasis and weight-related comorbidities.
|
| |
Key Details
|
| |
| • | Primary endpoint met: 27.1% achieved PASI 100 + ≥10% weight loss vs. 5.8% with Taltz monotherapy at 36 weeks.
|
|
| • | Key secondary: 40% relative increase in PASI 100 rates (40.6% vs. 29%) with combination.
|
|
| |
Next Steps
Full results for future publication; regulatory discussions planned for integrated strategies.
|
| |
Asset Snapshot
Dual IL-17A + GIP/GLP-1 approach addressing inflammation and metabolic health in psoriasis.
|
| |
TOGETHER-PsO highlights Lilly's paradigm for combined dermatology and weight management.
Pediatric Ulcerative Colitis (UC)
|
| |
Takeda reports positive Phase III KEPLER topline results for IV ENTYVIO (vedolizumab) in children/adolescents (2–17 years) with moderate-to-severe UC and inadequate response to conventional/TNF therapies.
|
| |
Key Details
|
| |
| • | Primary endpoint met: 47.3% clinical remission at Week 54.
|
|
| • | 34.7% remission at Week 14; 29% sustained remission at Weeks 14/54 (key secondary).
|
|
| • | Safety consistent with adult profile; no new signals in pediatrics.
|
|
| |
Next Steps
Presented at ECCO 2026 Congress; marketing applications planned for US, EU, and other markets.
|
| |
Asset Snapshot
Expands ENTYVIO into pediatric UC, addressing unmet needs in young IBD patients.
|
| |
KEPLER positions Takeda for leadership in pediatric gastroenterology.
|
| |
|
| |
| | Biopharma Regulatory Updates: Approvals & Clearances
|
|
|
|
|
| |
Regulatory Moves Reshape the Biopharma Landscape
|
| |
|
| |
This week’s regulatory wave signals continued acceleration across oncology, immunology, cardiology, metabolic disease, and even animal health with pivotal approvals and filings positioning several companies for meaningful commercial inflection points.
|
| |
Here’s a sharp look at the latest milestones:
|
| |
| • | CStone Pharmaceuticals secured U.S. FDA IND clearance to initiate a Phase II trial of CS2009 in advanced solid tumors expanding its oncology development footprint into the U.S.
|
|
| • | GSK received European Commission approval for Exdensur (depemokimab) in asthma with Type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP), strengthening its respiratory immunology portfolio.
|
|
| • | Bristol Myers Squibb announced U.S. FDA acceptance of its NDA for an iberdomide combination regimen in relapsed/refractory multiple myeloma moving closer to expanding options in heavily pretreated patients.
|
|
| • | Cytokinetics reported EC approval of Myqorzo (aficamten) for obstructive hypertrophic cardiomyopathy (oHCM), advancing targeted cardiac muscle modulation in Europe.
|
|
| • | Novo Nordisk gained EC approval for a higher injectable dose of Wegovy, reinforcing its leadership in chronic weight management amid sustained global demand.
|
|
| • | ImmunityBio received EC conditional approval for Anktiva + BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) a critical step for patients with limited alternatives.
|
|
| • | Daiichi Sankyo announced EMA validation of its MAA for Enhertu in HER2-positive early breast cancer, signaling progress toward earlier-line expansion.
|
|
| • | Roche saw the U.S. FDA accept its NDA for giredestrant in ESR1-mutated, ER-positive advanced breast cancer potentially adding a next-generation endocrine therapy option.
|
|
| • | NexEos Bio obtained U.S. FDA IND clearance to advance NTX-1024 into a Phase II/III study for vernal keratoconjunctivitis, targeting a rare but burdensome ocular condition.
|
|
| |
From oncology breakthroughs and cardiometabolic leadership to rare diseases and veterinary innovation, this week’s regulatory momentum underscores a clear theme: pipelines are maturing, filings are accelerating, and global agencies remain highly active across therapeutic areas.
|
| |
The regulatory engine is running strong and the competitive landscape is evolving just as quickly.
|
| |
|
| |
| | MedTech Regulatory Update: Speed & Scalable Diagnostics
|
|
|
|
|
| |
MedTech Regulatory Moves: Speed and Precision
|
| |
|
| |
Regulatory momentum in MedTech continues to accelerate, with platforms designed to deliver faster, more accessible, and highly sensitive diagnostics gaining key clearances across major markets.
|
| |
Here are the latest highlights:
|
| |
| • | LEX Diagnostics received U.S. FDA 510(k) clearance and CLIA Waiver status for its VELO System, enabling the delivery of highly sensitive PCR results in near-patient settings. The dual milestone significantly expands access to molecular diagnostics by combining laboratory-grade accuracy with decentralized testing convenience unlocking broader adoption across clinics and point-of-care environments.
|
|
| • | Bio-Techne secured CE-IVD marking for its Ella Platform, supporting rapid, cartridge-based immunoassays designed for streamlined biomarker analysis. The approval strengthens the company’s position in automated protein quantification and facilitates expanded use across European clinical laboratories.
|
|
| |
Together, these milestones reinforce a clear trend in diagnostics: precision is moving closer to the patient, workflows are becoming more automated, and regulatory pathways are enabling scalable deployment of next-generation platforms across global markets.
|
| |
|
| |
| | Biosimilars Regulatory Moves: Access and Competition
|
|
|
|
|
| |
Regulatory Spotlight: Biosimilars Expand Access
|
| |
|
| |
The global biosimilars landscape continues to gain momentum, with fresh approvals and clinical clearances reinforcing the push toward broader patient access and cost-efficient biologic therapies.
|
| |
Here are the latest regulatory milestones:
|
| |
| • | STADA Arzneimittel and Bio-Thera Solutions received European Commission approval for Gotenfia, a biosimilar to Simponi (golimumab). The approval strengthens competition in the TNF inhibitor space across Europe and expands therapeutic options in chronic inflammatory diseases.
|
|
| • | Shanghai Henlius Biotech reported U.S. FDA IND clearance to initiate a Phase I trial of HLX15-SC, a biosimilar to Darzalex Faspro (daratumumab and hyaluronidase-fihj). The clearance marks an important step toward entering the high-value CD38-targeting multiple myeloma market.
|
|
| • | Accord BioPharma announced U.S. FDA approval of Filkri, a biosimilar to Neupogen (filgrastim), further intensifying competition in the supportive oncology care segment and reinforcing supply resilience.
|
|
| |
From immunology to oncology and hematology, these regulatory advancements highlight a consistent theme: biosimilars are not only expanding globally but also targeting increasingly complex biologics driving affordability, accessibility, and market dynamism worldwide.
|
| |
|
| |
| | $3.5B Deal and FDA Greenlight Reshape Vet Care
|
|
|
|
|
| |
Cencora & Covetrus Unite to Build a $3.5B Animal Health Powerhouse
|
| |
|
| |
Cencora and Covetrus have entered a definitive agreement to merge Covetrus with MWI Animal Health, creating a scaled, fully integrated platform for companion and large animal markets.
|
| |
Why It Matters
|
| |
| • | Mega Merger: $3.5B EV creates unified animal health distribution giant.
|
|
| • | Capital Structure: $1.25B cash + $800M preferred + $1.45B common equity.
|
|
| • | Ownership Play: Secures Cencora 34.3% stake with growth upside.
|
|
| • | Strategic Bet: Drives consolidation in vet supply chain ecosystem.
|
|
| |
Strategic Focus
|
| |
| • | Market Expansion: Serves companion and large animal segments end-to-end.
|
|
| • | Platform Power: Combines distribution, digital tools, and industry ties.
|
|
| • | Vet Care Push: Boosts affordability, access, and supply chain efficiency.
|
|
| • | Innovation Frontier: Enables tech-driven resilience in animal health.
|
|
| |
This move signals continued consolidation in animal health and a clear push toward building more resilient, tech-enabled, and customer-centric distribution models.
|
| |
FDA Greenlights NexGard & NexGard COMBO for Rapid New World Screwworm Control
|
| |
|
| |
The U.S. FDA has granted Emergency Use Authorization (EUA) for Boehringer Ingelheim’s NexGard chewables in dogs and NexGard COMBO topical for cats, targeting infestations caused by New World screwworm (NWS). Safe for puppies and kittens 8 weeks and older, these approvals deliver fast, effective protection for pets at risk.
|
| |
| | That’s a Wrap for This Week
We will see you next week
|
|
|
|
|
| |
$1.8B Deals, AI Breakthroughs & Global Expansion: Pharma in Motion
|
| |
This week, AI-driven macrocycles, $1B+ acquisitions, and late-stage clinical wins dominate biopharma headlines. From Unnatural Products’ landmark Novartis deal to Candel, Hims & Hers, and VB Spine strategic moves, plus pivotal regulatory approvals across oncology, immunology, cardiology, and animal health PharmaShots delivers the intelligence shaping global pharma and biotech.
|
| |
Stay Ahead with PharmaShots Weekly
|
| |
Biopharma never slows down overnight data can shift markets, billion-dollar deals redefine the competitive landscape, and regulatory moves redraw the rules of the game. Your intelligence can’t afford to lag.
|
| |
PharmaShots Weekly cuts through the noise, delivering what truly matters: pivotal pipeline updates, regulatory inflection points, clinical breakthroughs, competitive insights, and strategic transactions — all distilled into an executive-ready brief you can digest in minutes.
|
| |
Every Monday at 8:00 AM EST, get a decision-focused snapshot of the forces shaping global pharma and biotech curated for leaders who act on insight, not just information.
|
| |
If this edition sparked ideas, make that momentum consistent. Subscribe to PharmaShots Weekly for intelligence that’s concise, credible, and crafted for decision-makers across R&D, Competitive Intelligence, Strategy, and Business Development.
|
| |
Know someone who values signal over clutter? Forward this edition.
Spotted an insight worth amplifying? Share it on LinkedIn and tag us we celebrate sharp perspectives.
|
| |
The industry moves fast. Your intelligence should move faster.
|
| |
| | Tell your success story to world!
Reach out to us [email protected] for CXO Talks or viewpoint interview, because your story matters!
|
|
|
|
|
| |
|
0 comments